Adult Psychiatry· 16 min read
ADHD: Pathophysiology, Treatment Mechanisms, and Emerging Research
Attention deficit hyperactivity disorder is one of the most common psychiatric conditions in adults, and one of the most poorly understood. Roughly 4.4% of U.S. adults meet criteria for ADHD, but the majority were never diagnosed as children. Many spend years cycling through treatments for anxiety or depression before anyone thinks to evaluate for ADHD. For adults seeking ADHD treatment NC providers offer varying levels of depth, and understanding what the condition actually involves at a neurological level is the first step toward getting the right diagnosis.
ADHD treatment in NC varies widely in depth and quality. The gap between what ADHD actually is at a neurological level and how most patients experience diagnosis is significant. A thorough ADHD evaluation goes beyond a symptom checklist. It requires understanding prefrontal cortex function, neurotransmitter dynamics, and how those processes translate into the daily experience of distractibility, impulsivity, and executive dysfunction.
This article covers the neuroscience behind ADHD, what a comprehensive evaluation looks like, how ADHD treatment medications work at the receptor level, and what emerging research is exploring beyond standard treatment options.
What ADHD Actually Is: The Neuroscience
ADHD is not a willpower problem. It is a neurodevelopmental disorder rooted in measurable differences in brain structure, function, and chemistry. Understanding these differences is essential for accurate diagnosis and effective ADHD treatment in NC and beyond.
Prefrontal Cortex Hypofunction
The prefrontal cortex (PFC) is the brain region responsible for executive function: planning, impulse control, working memory, emotional regulation, and sustained attention. In ADHD, the PFC is consistently underactive. Imaging studies show reduced size and reduced functional activity of the right PFC in patients with ADHD, along with more disorganized white matter tracts connecting the PFC to other brain regions (1).
This matters clinically because the symptoms patients describe (losing track of conversations, forgetting appointments, acting impulsively, struggling to start tasks) are direct consequences of weakened PFC regulation. The PFC is supposed to act as the brain’s air traffic controller, coordinating information from sensory and motor areas. In ADHD, that controller is understaffed.
Dopamine and Norepinephrine Dysregulation
The PFC requires specific neurochemical conditions to function properly. Two catecholamines, dopamine (DA) and norepinephrine (NE), are critical. Dopamine acts primarily at D1 receptors to reduce neural “noise,” while norepinephrine acts at alpha-2A adrenoceptors to strengthen neural “signal” (2). Both follow an inverted U-shaped dose-response curve: too little or too much of either neurotransmitter impairs PFC function.
In ADHD, patients tend to have lower baseline levels of dopamine and norepinephrine in the PFC. Research has also identified higher density of dopamine transporters (DAT) in ADHD brains, meaning dopamine is reabsorbed too quickly before it can activate downstream receptors (3). The result is a PFC that cannot sustain the neurochemical environment it needs to regulate attention and behavior. Testosterone has an effect on dopamine and cognitive functioning as well.
The same reward circuitry is where GLP-1 drugs appear to blunt craving, a mechanism I dig into in GLP-1 medications and alcohol use.
Default Mode Network Dysregulation
The default mode network (DMN) is a set of brain regions that activates during rest and deactivates during focused tasks. In neurotypical brains, the DMN quiets down when concentration is needed. In ADHD, the DMN fails to deactivate properly, which means it intrudes on task-relevant brain activity (4). This is the neurological basis of mind wandering. The patient is not choosing to lose focus. Their DMN is literally competing with the brain regions trying to sustain attention.
Cortical Maturation Delays
Longitudinal imaging studies have shown that children with ADHD reach peak cortical thickness approximately three years later than neurotypical children, with the most pronounced delays occurring in the prefrontal regions (5). This finding helps explain why some patients experience symptom improvement in adulthood while others do not. For many adults with ADHD, the cortical maturation gap narrows but never fully closes.
Heritability
ADHD is among the most heritable psychiatric conditions. Twin studies estimate heritability at approximately 74% (6). Genetic research has identified alterations in genes affecting dopamine signaling (including the dopamine transporter gene SLC6A3 and the dopamine receptor D4 gene DRD4), norepinephrine pathways (including dopamine beta-hydroxylase, the enzyme that synthesizes norepinephrine), and synaptic development. If a parent has ADHD, their children have a significantly elevated risk.
How ADHD Is Evaluated in Adults
ADHD diagnosis in adults is more complex than in children because symptoms have had decades to intertwine with coping mechanisms, comorbid conditions, and life circumstances. There is no single test that confirms ADHD. Diagnosis requires a structured clinical evaluation by a qualified professional.
What a Thorough Evaluation Includes
A comprehensive adult ADHD evaluation typically covers a detailed developmental and psychiatric history going back to childhood, current symptom assessment using validated rating scales, assessment of functional impairment across work, relationships, and daily life, screening for comorbid conditions (anxiety, depression, bipolar disorder, substance use, sleep disorders), medical history review to rule out conditions that mimic ADHD (thyroid dysfunction, sleep apnea, vitamin deficiencies), and, when appropriate, collateral information from partners, family members, or prior records.
The evaluation is not a checklist exercise. It requires clinical judgment to determine whether a patient’s symptoms represent ADHD, another psychiatric condition, or both. Many adults with ADHD have developed compensatory strategies that mask core symptoms, making careful history-taking essential.
Why Misdiagnosis Happens
ADHD in adults is frequently misdiagnosed as generalized anxiety disorder, major depressive disorder, or bipolar II disorder. The overlap is real: ADHD causes chronic underperformance, which causes frustration and low self-esteem, which looks like depression. ADHD causes racing thoughts and restlessness, which looks like anxiety. ADHD causes impulsivity and emotional dysregulation, which can resemble mood cycling.
The distinguishing factor is onset. ADHD symptoms must have been present before age 12 (per DSM-5 criteria), even if they were never formally identified. A patient who developed concentration problems at age 30 after a major life stressor is more likely experiencing something other than ADHD. A patient who has “always been this way” and was labeled the “smart kid who doesn’t try” is a very different clinical picture.
How ADHD Treatment Medications Work
Understanding how ADHD treatment medications work at the receptor level helps patients make informed decisions. All effective ADHD pharmacotherapies share a common mechanism: they enhance catecholamine signaling in the prefrontal cortex.
Stimulants (Methylphenidate and Amphetamine Classes)
Stimulant medications are the first-line treatment for ADHD and the most extensively studied. Methylphenidate (Concerta, Ritalin, Focalin) primarily blocks the reuptake of dopamine and norepinephrine by inhibiting DAT and NET transporters. Amphetamines (Adderall, Vyvanse) both block reuptake and actively promote the release of dopamine and norepinephrine from presynaptic neurons (7).
At therapeutic doses, stimulants preferentially increase norepinephrine and, to a lesser extent, dopamine in the PFC. This is a critical point: the therapeutic effect is about optimizing PFC catecholamine levels, not flooding the brain with dopamine. The inverted U-shaped dose-response curve means that doses too high will actually impair PFC function and worsen symptoms (8).
Non-Stimulants (Atomoxetine)
Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor. It blocks NET in the prefrontal cortex, increasing norepinephrine availability. Because NET also transports dopamine in the PFC (where DAT expression is relatively low), atomoxetine effectively increases both norepinephrine and dopamine concentrations in the prefrontal cortex without significantly affecting dopamine levels in the nucleus accumbens (9). This is why atomoxetine has minimal abuse potential compared to stimulants.
Alpha-2 Agonists (Guanfacine and Clonidine)
Guanfacine (Intuniv) and clonidine (Kapvay) work by directly stimulating postsynaptic alpha-2A adrenoceptors in the PFC. Rather than increasing the amount of norepinephrine available, they mimic its effects at the receptor. Guanfacine strengthens PFC network connectivity by closing HCN (hyperpolarization-activated cyclic nucleotide-gated) channels on dendritic spines, which strengthens synaptic connections between PFC neurons (10). These medications are particularly useful as adjuncts to stimulants or for patients who cannot tolerate stimulants.
Emerging Research: What Science Is Exploring Beyond Standard Treatment
Standard ADHD pharmacotherapy is effective for the majority of patients, but approximately 30% do not respond adequately to stimulants or cannot tolerate their side effects. This has driven interest in alternative and adjunctive approaches, some of which overlap with emerging peptide research for mood and cognitive disorders. The following compounds are in various stages of research. None are FDA-approved for ADHD, and this section is informational, not a treatment recommendation.
Saffron (Crocus sativus)
Saffron is one of the few natural compounds with actual randomized controlled trial data in ADHD. A 2019 double-blind RCT compared saffron (20 to 30 mg per day) to methylphenidate in 54 children with ADHD over six weeks. The study found no significant difference between the two groups on Parent and Teacher ADHD Rating Scale scores (11). A subsequent non-randomized study found comparable efficacy between saffron and methylphenidate, with saffron showing particular effectiveness for hyperactivity symptoms and additional benefit for sleep onset time (12). A 2022 RCT further found that combining saffron with methylphenidate produced greater symptom improvement than methylphenidate alone (13).
The proposed mechanism involves saffron’s active compounds (crocin and safranal) facilitating the release of serotonin, dopamine, and norepinephrine. The evidence is promising but early. Sample sizes are small, study durations are short, and the majority of research has been conducted in pediatric populations. Larger, longer trials are needed before saffron can be considered a validated treatment option. I go through the newer saffron research, including the adult trial, in my guide to supplements for ADHD. For more on the broader landscape of emerging compounds, see Peptide Therapy in North Carolina.
Bromantane
Bromantane (marketed in Russia as Ladasten) has a mechanism of action that is fundamentally different from conventional stimulants. Rather than blocking dopamine reuptake or promoting dopamine release, bromantane upregulates the expression of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AAAD), the two key enzymes in dopamine biosynthesis (14). This means it enhances the brain’s capacity to produce dopamine rather than manipulating existing dopamine stores.
Animal studies have shown this upregulation to be rapid, pronounced, and long-lasting, without the tolerance, withdrawal, or addictive potential associated with conventional stimulants (15). Bromantane also demonstrates anxiolytic properties, which is unusual for a compound that enhances dopaminergic activity. It is approved in Russia for neurasthenia but has not undergone rigorous clinical trials for ADHD specifically. The dopamine synthesis enhancement mechanism is mechanistically relevant to ADHD pathophysiology, but clinical data in ADHD populations does not yet exist.
Semax and Selank
Semax and Selank are synthetic peptides with potential relevance to ADHD through their effects on neurotrophic factors and neurotransmitter systems. Semax, a synthetic analog of ACTH(4-10), has been shown to modulate BDNF (brain-derived neurotrophic factor) and influence dopaminergic and serotonergic systems. Selank, derived from the endogenous peptide tuftsin, primarily affects GABAergic and serotonergic transmission with anxiolytic properties. Both are approved in Russia for various neurological indications. Their relevance to ADHD is theoretical and based on their neurotransmitter modulation profiles rather than direct clinical evidence in ADHD populations. For a deeper discussion of these peptides, see Semax and Selank: What the Research Shows.
BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein found in human gastric juice. Research has demonstrated interactions with the dopaminergic system, including modulation of dopamine receptor sensitivity and potential neuroprotective effects. Its relevance to ADHD is indirect but mechanistically plausible given the central role of dopamine dysregulation in ADHD pathophysiology. The existing research is primarily preclinical. For a comprehensive review of BPC-157 research, see BPC-157: What the Research Actually Shows.
GLP-1 Receptor Agonists and ADHD
GLP-1 receptor agonists (semaglutide, tirzepatide) have generated significant public interest for potential ADHD benefits after anecdotal reports from patients taking these medications for weight management. GLP-1 receptors are present in brain regions involved in reward processing, and these medications modulate dopaminergic signaling in the mesolimbic pathway (16). Some patients report reduced impulsivity and improved focus while taking GLP-1 agonists.
The scientific reality as of early 2026: there are no published randomized controlled trials examining GLP-1 agonists for ADHD. Any reported improvements could reflect indirect effects of better sleep (from weight loss reducing sleep apnea), improved metabolic health, reduced inflammation, or placebo response. GLP-1 agonists should not replace proven ADHD treatments. However, for patients with comorbid ADHD and obesity or metabolic syndrome, the potential intersection between metabolic health and cognitive function is worth discussing with a psychiatrist. Baghel Psychiatry offers both ADHD evaluation and medical weight loss services, which allows for integrated management of both conditions.
MOTS-c, SS-31, and MIF-1
These peptides represent earlier-stage research with theoretical relevance to ADHD. MOTS-c is a mitochondrial-derived peptide involved in metabolic signaling and neuroprotection, relevant to the mitochondrial dysfunction hypothesis of ADHD. SS-31 (elamipretide) targets cardiolipin on the inner mitochondrial membrane and has demonstrated neuroprotective properties in preclinical models. MIF-1 (PLG) is a tripeptide that modulates dopamine receptor sensitivity and has older, underexplored research directly relevant to ADHD dopamine pathology. All three require significant additional research before any clinical conclusions can be drawn.
Noopept
Noopept is a synthetic dipeptide that modulates BDNF and NGF (nerve growth factor) expression. Its relevance to ADHD is based on the role of neurotrophic factors in prefrontal cortex development and function. Direct evidence for ADHD-specific benefits is thin, and the compound remains primarily of interest to the nootropic research community rather than mainstream psychiatry.
ADHD Treatment in NC: Access and Options
Access to comprehensive ADHD treatment in NC can be challenging. Wait times at academic medical centers and specialized clinics frequently stretch to several months. Many primary care providers are uncomfortable diagnosing adult ADHD, particularly in patients with complex presentations or comorbid conditions.
Telehealth has changed this significantly. A thorough ADHD evaluation does not require in-person testing. The clinical interview, symptom rating scales, developmental history, and comorbidity screening that form the core of a comprehensive evaluation can all be conducted effectively via secure video. Telehealth also eliminates geographic barriers, making specialist-level ADHD treatment accessible to patients across the entire state. For patients exploring cash-pay psychiatry in North Carolina, telehealth also simplifies the process by removing insurance-related delays and pre-authorization requirements.
Dr. Shantanu Baghel, DO is a board-certified psychiatrist (ABPN) who conducts comprehensive ADHD evaluations via telehealth for adults throughout North Carolina. Evaluations include detailed psychiatric history, validated symptom assessments, and comorbidity screening. For patients whose ADHD overlaps with other conditions, Dr. Baghel also offers testosterone replacement therapy and medical weight loss services under one treatment plan. Learn more about all available services at Psychiatry Services.
Frequently Asked Questions
Can adults be diagnosed with ADHD for the first time?
Yes. Many adults with ADHD were never diagnosed as children, particularly if they had the predominantly inattentive presentation (formerly called ADD) rather than the hyperactive-impulsive type. DSM-5 criteria require that some symptoms were present before age 12, but a formal childhood diagnosis is not required. A skilled evaluator can identify childhood symptoms retrospectively through careful history-taking, even in patients who performed well academically by compensating with intelligence or extra effort.
What is the difference between a psychiatrist and a psychologist for ADHD evaluation?
Both can diagnose ADHD. Psychologists may offer neuropsychological testing, which can be useful in complex cases but is not required for diagnosis. Psychiatrists are physicians who can both diagnose and prescribe medication, including controlled substances like stimulants. For patients who want evaluation and treatment from the same provider, a psychiatrist offers a streamlined path. For patients who want extensive cognitive testing, a neuropsychologist may be appropriate as a complement.
Can ADHD be diagnosed via telehealth?
Yes. The core components of an ADHD evaluation (clinical interview, symptom rating scales, psychiatric history, and comorbidity screening) do not require physical examination or in-person testing. Telehealth evaluations allow the clinician to observe the patient in their natural environment, which can actually provide additional diagnostic information. Both the American Psychiatric Association and state medical boards recognize telehealth as appropriate for ADHD evaluation and management, including prescribing stimulant medications when indicated.
How much does ADHD treatment in NC cost without insurance?
At Baghel Psychiatry, the monthly plan is $250 per month and covers up to four visits a month, including evaluation, ongoing medication management, and follow-up appointments. There are no separate evaluation fees. Labs and medications are not included and are paid separately by the patient. The same fee covers your testosterone replacement therapy visits when TRT is part of your care. See Psychiatry Services for full pricing details.
How long does an ADHD evaluation take?
A thorough initial evaluation takes 45 to 60 minutes. It includes a comprehensive psychiatric interview, review of symptom patterns across the lifespan, screening for comorbid conditions, and a discussion of treatment options. Some patients may benefit from a second visit to review collateral information or complete additional screening measures.
Are peptides and supplements a replacement for ADHD medication?
No. The compounds discussed in the emerging research section of this article (saffron, bromantane, semax, selank, BPC-157, and others) are not FDA-approved for ADHD and should not be used as replacements for evidence-based treatment. Stimulant and non-stimulant medications remain the standard of care for ADHD. Some of these compounds may eventually prove useful as adjunctive therapies, but the current evidence base is insufficient to recommend them for ADHD treatment. Any patient interested in these approaches should discuss them with a psychiatrist who can evaluate risks and potential interactions.
Schedule ADHD Treatment in NC
Dr. Baghel offers comprehensive ADHD evaluation and treatment via telehealth for adults across North Carolina. Board-certified in general and forensic psychiatry (ABPN). New patients welcome.
Or call (910) 612-6015
Monthly plan covers Dr. Baghel’s clinical services only (evaluation, monitoring, medication management, ongoing care). Labs and medications are not included and are paid separately by the patient.
References
1. Arnsten AFT. The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex. J Pediatr. 2009;154(5):I-S43. PMID: 20596295.
2. Arnsten AFT, Pliszka SR. Catecholamine Influences on Prefrontal Cortical Function: Relevance to Treatment of Attention Deficit Hyperactivity Disorder and Related Disorders. Pharmacol Biochem Behav. 2011;99(2):211-216. PMC3129015.
3. del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The Roles of Dopamine and Noradrenaline in the Pathophysiology and Treatment of Attention-Deficit/Hyperactivity Disorder. Biol Psychiatry. 2011;69(12):e145-e157. PMID: 21550021.
4. Whitfield-Gabrieli S, Ford JM. Default Mode Network Activity and Connectivity in Psychopathology. Annu Rev Clin Psychol. 2012;8:49-76. PMID: 22224834.
5. Shaw P, Eckstrand K, Sharp W, et al. Attention-Deficit/Hyperactivity Disorder Is Characterized by a Delay in Cortical Maturation. Proc Natl Acad Sci USA. 2007;104(49):19649-19654. PMID: 18024590.
6. Faraone SV, Larsson H. Genetics of Attention Deficit Hyperactivity Disorder. Mol Psychiatry. 2019;24(4):562-575. PMID: 29892054.
7. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. Cambridge University Press; 2013.
8. Berridge CW, Devilbiss DM. Psychostimulants as Cognitive Enhancers: The Prefrontal Cortex, Catecholamines, and Attention-Deficit/Hyperactivity Disorder. Biol Psychiatry. 2011;69(12):e101-e111. PMID: 20875636.
9. Correa M, et al. An Overview on Neurobiology and Therapeutics of Attention-Deficit/Hyperactivity Disorder. Pharmaceutics. 2023;15(9):2206. PMC10501041.
10. Arnsten AFT. Guanfacine’s Mechanism of Action in Treating Prefrontal Cortical Disorders: Successful Translation Across Species. Neurobiol Learn Mem. 2020;176:107327. PMID: 33075480.
11. Baziar S, Aqamolaei A, Khadem E, et al. Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study. J Child Adolesc Psychopharmacol. 2019;29(3):205-212. PMID: 30741567.
12. Blasco-Fontecilla H, et al. Effectivity of Saffron Extract (Saffr’Activ) on Treatment for Children and Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD): A Clinical Effectivity Study. Nutrients. 2022;14(19):4046. PMC9573091.
13. Khaksarian M, Ahangari N, Masjedi-Arani A, et al. A Comparison of Methylphenidate (MPH) and Combined Methylphenidate with Crocus sativus (Saffron) in the Treatment of Children and Adolescents with ADHD: A Randomized, Double-Blind, Parallel-Group, Clinical Trial. Iran J Psychiatry Behav Sci. 2021;15(3):e108390.
14. Mikhaylova M, et al. The Effects of Ladasten on Dopaminergic Neurotransmission and Hippocampal Synaptic Plasticity in Rats. Neuropharmacology. 2007;53(5):601-608. PMID: 17854844.
15. Vakhitova IuV, Iamidanov RS, Seredinin SB. Ladasten Induces the Expression of Genes Regulating Dopamine Biosynthesis in Various Structures of Rat Brain. Eksperimental’naia i Klinicheskaia Farmakologiia. 2003;67(4):7-11. PMID: 15500036.
16. Xiang L, Peng Y. Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study. Int J Mol Sci. 2025;26(6):2741. PMC11942543.